Effect of Interleukin-2 on Antitumor Response Against Subcutaneous Meth-A Tumor in Mice

마우스에서 Meth-A 종양세포에 대한 Interleukin-2의 항암효과

  • 권오덕 (전북대학교 수의과대학)
  • Published : 2000.12.01

Abstract

Recombinant inteileukin-2 (IL-2) is a potent inductive stimulus for nitric oxide synthesis (NO.) and has been demonstrated as an antineoplastic agent in mice and human. But it is not let clear whether NO. can contribute to IL-2-induced therapeutic responses. Therefore, the current experiment was undertaken to clarify the effect of IL-2 on antitumor response against subcutaneous Meth-A tumor in mice. At the beginning of each experiment, normal BALB/c mice were injected subcuta-neously with $5{\times}10^6 Meth-A$ tumor cells. Some mice were implanted with osmotic minipumps con- taining 225 $\mu$l of 3.38 M $N^{\gamma}$ -monomethyl-L-arginine (MLA. an NOS inhibitor). Beginning on day 7, experimental groups were treated with a f-day course of IL-2 (50,000 lU,75,000 nJ,100,0007, 50,000 IU+MLA, 75,000 IU+MLA, 100,000 IU+MLA intraperitoneal injection every 12 hours for 5 days). The result of this experiment revealed that Meth-A tumor grew progressively in control mice. Intraperitoneal IL-2 treatment decreased tumor growth and prolonged survival. compared with con-trol mice. But no significant differences among 50.000 lU.75.000 lU and 100,000 lU of 7-2 treat-ment were observed. MLA administration prevented partially the decrease tumor growth and prolong survival of IL-2 treated mice compared with mice receiving IL-2 alone.

Keywords

References

  1. Cancer Res v.50 Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor Blay JY;Favrot MC;Negrier S;Combaret V;Chouaib S;Mercatello A;Kaemmerlen P;Franks CR;Phillip T
  2. Cancer Res v.50 Adoptive immunotherapy of human cancer. The cytokine cascade and monocyte activation following high-dose interleukin-2 bolus treatment Boccoli G;Masciulli R;Ruggeri EM;Carlini P;Giannelia G;Montesoro E;Mastroberadino G;Isacchi G;Testa U;Calabresi F(et al)
  3. Int J Cancer v.10 Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors Borberg H;Octtgen HF;Choudry K;Beattie EJ
  4. Cancer Immunol Immunother v.49 Killing of Fas ligand-resistant renal carcioma cells by interleukin-2 and BCG-activated effector cells Brandau S;Sultmann H;Fjad HD;Jocham D;Bohle A
  5. Blood v.93 Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production Cifone MG;D'Alo S;Parroni R;Millimaggi D;Biordi L;Martinotti S;Santoni A
  6. Clin Cancer Res v.6 Phase II trial of interleukin 2,interferon alpha,and 5-fluorouracil in metastatic renal cell cancer:a cytokine working group study Dutcher JP;Logan T;Gordon M;Sosman J;Weiss G;Margolin K;Plasse T;Mier J;Lotze M;Clark J;Atkins M
  7. J.Exp.Med v.170 Passive immunization against tumor neerrosis factor partially abrogates interleukin-2 toxicity Fraker DL;Langstein HN;Norton JA
  8. Cancer Res v.48 Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells Gelmo BT;Palladino MA Jr;Jeffe HS;Espevik TP;Rayner AA
  9. Biochem Biophys Res Commun v.157 Nitric oxide A cytotoxic activated macrophage effector molecule Hibbs JB Jr;Taintor RR;Vavrin Z;Rachlin C
  10. J Clin Invest v.89 Evidence for cytokine inducible nitric oxide synthesis from Larginine in patients receiving interleukin-2 therapy Hibbs JB Jr;Westenfelder C;Taintor RR;Vavrin Z;Kablitz,C;Baranowski RL;Ward JH;Menloce RL;McMurry MP;Kushner JP;Samlowski WE
  11. J.Urol v.160 Nitric oxide synthase activity in human renal cell carcinoma Jansson OT;Morcos E;Brundin L;Bergerheim US;Adolfsson J;Wiklund NP
  12. Scand J Immunol v.52 Interleukin-2-induced nitric oxide synthesis and nuclear factor-kappa B activity in activated natural killer cells and the production of interferon-gamma Jyothi MD;Khar A
  13. J Immunol v.143 Induction of endogeneous cytokine mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients Kasid A;Director EP;Rosenberg SA
  14. Cancer Res v.45 Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2 La Freniere R;Rosenberg SA
  15. Eur Surg Res v.28 Inhibition of nitric oxide synthesis does not improve interleukin-2-mediated antitumor effects in vivo Leder GH;Oppenheim M;Rosenstein M;Shah N;Hoffman R;Lotze MT;Beger HG
  16. Anticancer Res v.20 Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response Lee SG;Heo DS;Yoon SJ;Jee YS;Kang JO;Kim K;Kim CD;Sung MW;Kim NK
  17. Cancer Res v.41 Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor Lotze MT;Grimn EA;Mazumder A;Strausser JI;Rosenberg SA
  18. Semin Oncol v.27 Interleukin-2 in the treatment of renal cancer Margolin KA
  19. Immunol v.172 Human interleukin-2 molecular biology,physiology and clinical possibilities Mertelsmann R;Welte K;
  20. J Clin Immuno v.8 Induction of circulating tumor necrosis factor (TNFa) as the mechanism for the febrile response to interleukin-2(IL-2)in cancer patients Mier JW;Vachino G;Van Der Meer JWM;Numerof RP;Adams S;Cannon JG;Bernheim HA;Atkins MB;Parkinson DR;Dinarello CA
  21. Cancer Immunol Immunother v.42 Effects of N(g)-methyl-L-arginine,and inhibitor of nitric oxide synthesis, on interleukin-2-induced capillary leakage and antitumor responses in healthy and tumor-bearing mice Orucevic A;Lala PK
  22. Ann Int Med v.108 New approach to the immunotherapy of cancer using interleukin-2 Rosenberg SA;Lotze MT;Mule JJ
  23. Nitric Oxide v.2 Nitric oxide exposure inhibits induction of lymphokine-activated killer cells by inducing precursor apoptosis Samlowski WE;Yim CY;McGregor JR
  24. J Immunother v.18 Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice Samlowski WE;Yim CY;McGregor JR;Kwon OD;Gonzales S;Hibbs JB Jr
  25. J Exp Med v.169 A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells Stuher DJ;Nathan CF;Nitric oxide
  26. Cancer Res v.55 Macrophage nitric oxide synthesis delays progression of ultraviolet light induced murine skin cancers Yim CY;Bastian NR;Smith JC;Hibbs JB Jr;Samlowski WE
  27. Korean J Intern Med v.11 Effects of nitric oxide(NO) synthesis inhibition on antitumor responses during interleukin-2 (IL-2) treatment of mice Yim CY;Lee CW;Choi SM;Park SS;Lee SJ;Kim JH;Song JS;Yoo WH;Kwak JY;Sohn MH
  28. J Immunol v.155 Nitric oxide synthesis contributes to IL-2-induced antitumor response against intraperitoneal Meth A tumor Yim CY;McGregor JR;Kwon OD;Bastian NR;Rees M;Mori M;Hibbs JB Jr;Samlowski WE